NICE CEO announces new approach to prioritization
The British drug pricing agency NICE is working on new guidelines for how to evaluate new products in a socioeconomic context. But it comes with the risk of an increase in healthcare inequality, the agency’s CEO warns in an interview with Medwatch.
by Leonora Beck
Should healthcare bodies asses new drugs and medical equipment based on the effect and isolated costs of the products? Or should they take secondary effects, such as the number of days a patient does not have to spend in a costly hospital bed, into consideration as well? Or the value a depressive individual could give back to society, if the proper medicine gets that person off of government benefits?
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
